Your session is about to expire
← Back to Search
Monoclonal Antibodies
XTMAB-16 for Sarcoidosis
Phase 2
Waitlist Available
Research Sponsored by Xentria, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is looking at the long-term safety and effectiveness of a drug called XTMAB-16 in patients with pulmonary sarcoidosis, which may or may not involve other parts of the body.
Who is the study for?
This trial is for patients with pulmonary sarcoidosis who completed the XTMAB-16-201 study. They should have finished either Week 12 or Week 24 assessments and must be on a stable steroid dose for at least two weeks before starting this extension study.
What is being tested?
The trial is testing the long-term safety and effectiveness of a drug called XTMAB-16 in treating pulmonary sarcoidosis, which may also affect other parts of the body. It's an open-label extension, meaning everyone knows they're getting XTMAB-16.
What are the potential side effects?
While specific side effects are not listed here, participants will be monitored for any adverse reactions to XTMAB-16 since it's evaluating long-term safety.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: XTMAB-16 TreatmentExperimental Treatment1 Intervention
Dose to be established in the XTMAB-16-201 Study.
Find a Location
Who is running the clinical trial?
Xentria, Inc.Lead Sponsor
6 Previous Clinical Trials
952 Total Patients Enrolled
1 Trials studying Sarcoidosis
94 Patients Enrolled for Sarcoidosis